Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Hepatitis Drug Development Pipeline Review 2017: 182 Products in Development & 100 Companies Profiled - Research and Markets

Research and Markets
Posted on: 04 Aug 17

The "Hepatitis Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology are fielding two pipeline products in this area, while all other companies are fielding only one. In hepatitis D there are a total of 12 products in development, by nine companies and one academic institution. Key companies operating in this pipeline space include EigerBioPharmaceuticalsand Replicor.

There are a total of 182 products in development for hepatitis B, by 110 companies and 14 academic institutions. Key companies operating in this pipeline space include Arbutus Biopharma, F. Hoffmann-La Roche, Johnson & Johnson, Assembly Biosciences, Gilead Sciences and InstitutoButantan. There are a total of 199 products in development for hepatitis C, by 92 companies and 34 academic institutions. Key companies operating in this pipeline space include Merck & Co, AbbVie, Johnson & Johnson, Gilead Sciences, Cocrystal Pharma, Bristol-Myers Squibb and F. Hoffmann-La Roche.

While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.

The report "Hepatitis Drug Development Pipeline Review, 2017", provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.

Companies Mentioned

  • Bukwang Pharm Co Ltd
  • CaroGen Corp
  • Celltrion Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Chromis Therapeutics Inc
  • Cocrystal Pharma Inc
  • Conatus Pharmaceuticals Inc
  • ContraVir Pharmaceuticals Inc
  • CyTuVax BV
  • DEKK-TEC Inc
  • Delpor Inc
  • Dicerna Pharmaceuticals Inc
  • Dong-A Socio Holdings Co Ltd
  • Dynavax Technologies Corp
  • eTheRNA Immunotherapies NV
  • Eiger BioPharmaceuticals Inc
  • Ensemble Therapeutics Corp
  • Enyo Pharma SA
  • F. Hoffmann-La Roche Ltd
  • Formune SL
  • Medivir AB
  • Merck & Co Inc
  • Microbio Co Ltd
  • (100+ Others)

Key Topics Covered:

1. Research Report Guidance

2. Executive Summary

3. Hepatitis Report Coverage

4. Therapeutics Development

5. Therapeutics Assessment

6. Companies Involved in Therapeutics Development

7. Dormant Projects

8. Discontinued Products

9. Product Development Milestones

For more information about this report visit

View source version on

Business Wire

Last updated on: 04/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.